Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort

[1]  Shawn X. Sun,et al.  Burden of Illness and Treatment Patterns Among Patients With von Willebrand Disease in US Clinical Practice , 2023, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[2]  X. Kurz,et al.  Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe , 2022, Frontiers in Pharmacology.

[3]  F. Roodhooft,et al.  Variability drivers of treatment costs in hospitals: A systematic review. , 2021, Health policy.

[4]  F. Galactéros,et al.  Coût des maladies rares en France en 2017 : une analyse des données du Système national des données de santé sur cinq pathologies , 2020 .

[5]  S. Susen,et al.  Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study , 2020, Journal of thrombosis and haemostasis : JTH.

[6]  V. Boulanger,et al.  Establishing Patient Registries for Rare Diseases: Rationale and Challenges , 2020, Pharmaceutical Medicine.

[7]  E. Berntorp,et al.  Bleeding‐related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  J. Eikenboom,et al.  Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  Ruchika Sharma,et al.  Advances in the diagnosis and treatment of Von Willebrand disease. , 2017, Blood.

[10]  V. Kaur,et al.  von Willebrand Disease: A Concise Review and Update for the Practicing Physician , 2017, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[11]  F. Leebeek,et al.  Current and Emerging Options for the Management of Inherited von Willebrand Disease , 2017, Drugs.

[12]  C. Kessler,et al.  Efficacy and safety of a VWF/FVIII concentrate (wilate®) in inherited von Willebrand disease patients undergoing surgical procedures , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  A. Kulikov,et al.  Pharmacoeconomic analysis of von willebrand factor/blood clotting factor viii concentrate (wilate) in the management of patients with von willebrand disease , 2015 .

[14]  E. Seifried,et al.  Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study. , 2015, Thrombosis research.

[15]  A. Cipolla,et al.  Cost-Consequences Analysis of the Long-Term Prophylaxis In A Type 1 Von Willebrand Disease Patient With Recurrent Bleedings In Italy. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  G. Dolan,et al.  Enhancing haemophilia care through registries , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  P. Boisseau.  Techniques de génétique moléculaire , 2014 .

[18]  É. Fressinaud.  Clinical, biological and molecular diagnosis , 2014 .

[19]  L. Valentino,et al.  von Willebrand factor/factor VIII concentrate (Humate‐P) for management of elective surgery in adults and children with von Willebrand disease , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  A. Iorio,et al.  Management of Inherited von Willebrand Disease in Italy: Results from the Retrospective Study on 1234 Patients , 2011, Seminars in thrombosis and hemostasis.

[21]  G. Barillari,et al.  Efficacy and safety of highly purified, doubly virus‐inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  P. Mannucci,et al.  von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery , 2007, Journal of thrombosis and haemostasis : JTH.

[23]  P. Mannucci,et al.  Impact, Diagnosis and Treatment of von Willebrand Disease , 2000, Thrombosis and Haemostasis.

[24]  Sultan,et al.  Clinical management of patients with von Willebrand’s disease with a VHP vWF concentrate: the French experience , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.